The role of cilostazol in the treatment of intermittent claudication

References

• Bradbury AW. The role of cilostazol (Pletal) in the management of intermittent claudication. Int J Clin Pract 2003;57:405–9
   PubMed Web of Science ®Google Scholar
• Hiatt WR. Medical treatment of peripheral arterial disease and claudication. New Engl J Med 2001;344:1608–21
   PubMed Web of Science ®Google Scholar
• Binnie A, Perkins J, Hands L. Exercise and nursing therapy for patients with intermittent claudication. J Clin Nursing 1999;8:190–200
   Google Scholar
• Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026–49
   PubMed Web of Science ®Google Scholar
• Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1996;1:60–4
   PubMedGoogle Scholar
• Davies A. The practical management of claudication. Br Med J 2000;321:911–2
   PubMed Web of Science ®Google Scholar
• Criqui MH. Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease. Am J Cardiol 2001;88(Suppl):43J–47J
   Google Scholar
• Burns P, Gough S, Bradbury A. Management of peripheral arterial disease in primary care. Br Med J 2003;326:584–8
   Google Scholar
• TASC Working Group. Management of peripheral arterial disease: Transatlantic Intersociety Consensus (TASC). Eur J Vasc Endovasc Surg 2000;19(Suppl A):S1–244
   Google Scholar
• Dormandy JA, Mahir MS. The natural history of peripheral atheromatous disease of the legs. In: Greenhalgh RM, Jamieson CW, Nicolaides AN, editors. Vascular surgery: issues in current practice. London: Grune & Stratton; 1986. p. 3–17
   Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). Drug therapy for peripheral vascular disease. Edinburgh: Royal College of Physicians; July 1998
   Google Scholar
• Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham study. J Am Geriatr Soc 1985;33:13–8
   PubMed Web of Science ®Google Scholar
• Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96:44–9
   PubMed Web of Science ®Google Scholar
• Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. New Engl J Med 1991;324:1149–55
   PubMed Web of Science ®Google Scholar
• Burns P, Lima E, Bradbury AW. What constitutes best medical therapy for peripheral arterial disease? Eur J Vasc Endovasc Surg 2002;24:6–12
   PubMedGoogle Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601–10
   Google Scholar
• Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand 1987;221:253–60
   PubMed Web of Science ®Google Scholar
• Beckmann JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. J Am Med Assoc 2002;287:2570–81
   Google Scholar
• American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333–41
   PubMed Web of Science ®Google Scholar
• Krentz AJ. Churchill’s pocketbook of diabetes. London: Churchill Livingstone; 2003. p. 40
   Google Scholar
• UKPDS Study Group [UKPDS 33]. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352: 837–53
   Google Scholar
• UKPDS Study Group [UKPDS 34]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352: 854–65
   Google Scholar
• Adler AI, Stratton IM, Neil HAW, et al. on behalf of the UKPDS Study Group [UKPDS 36]. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. Br Med J 2000;321: 412–9
   Google Scholar
• UKPDS Study Group [UKPDS 38]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998;317: 703–13
   Google Scholar
• Boccalon H. Intermittent claudication in older patients. Practical treatment guidelines. Drugs Aging 1999;14:247–59
   Google Scholar
• Collins R, Armitage J, Parish S, et al. [Heart Protection Study Collaborative Group]. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005–16
   Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333–5
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;341:410–18
   Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. [West of Scotland Coronary Prevention Study Group]. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301–7
   Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med 1987;317;1237–4
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349–57
   Google Scholar
• Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 – BHS IV. J Hum Hypertens 2004;18:139–85
   PubMed Web of Science ®Google Scholar
• Brown MJ, Cruickshank JK, Dominiczak AF, et al., for the Executive Committee, British Hypertension Society. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17: 81–6
   Google Scholar
• Ostergren J, Sleight P, Dagenais G, et al. [HOPE study investigators]. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17–24
   Google Scholar
• Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320–31
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39
   PubMed Web of Science ®Google Scholar
• Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787–800
   Google Scholar
• Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. Vasc Surg 2003;38:710–3
   Google Scholar
• Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg. 2003;26:1–16
   PubMed Web of Science ®Google Scholar
• Clifford PC, Davies PW, Hayne JA, Baird RN. Intermittent claudication. Is a supervised exercise class worthwhile? Br Med J 1980;280:1503–5
   Google Scholar
• Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23:104–15
   Google Scholar
• Curci JA, Sanchez LA. Medical treatment of peripheral arterial disease. Curr Opin Cardiol 2003;18:425–30
   PubMed Web of Science ®Google Scholar
• Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 2002;112:49–57
   PubMed Web of Science ®Google Scholar
• Cheetham DR, Burgess DR, Ellis M, et al. Does supervised exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent claudication? A randomised trial. Eur J Vasc Endovasc Surg 2004;27:17–23
   PubMed Web of Science ®Google Scholar
• Bick C. Intermittent claudication. Nursing Standard 2003;17:45–52
   PubMedGoogle Scholar
• Chapman T, Goa KL. Cilostazol. A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003;3:117–38
   PubMedGoogle Scholar
• Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999;178:141–6
   PubMed Web of Science ®Google Scholar
• Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial disease. Chest 1998;114:666–82S
   Google Scholar
• Perkins JM, Collin J, Creasy TS, et al. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 1996;11:409–13
   PubMed Web of Science ®Google Scholar
• Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial. J Vasc Surg 1997;26:551–7
   PubMed Web of Science ®Google Scholar
• Bradbury AW. The management of intermittent claudication. Geriatric Med 2003;33:1–4
   Google Scholar
• Pletal® (cilostazol) Summary of Product Characteristics
   Google Scholar
• Pletal product monograph. Otsuka Pharmaceutical Europe Limited. January 2003
   Google Scholar
• Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314–9
   PubMed Web of Science ®Google Scholar
• Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized multicentre study. Arch Intern Med 1999;159:2041–50
   PubMed Web of Science ®Google Scholar
• Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87(Suppl):28–33D
   Google Scholar
• Elam MB, Heckman MD, Crouse MD, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18:1942–7
   PubMed Web of Science ®Google Scholar
• Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35: 48–56
   Google Scholar
• Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle culture. J Cardiovasc Pharmacol 1992;20:900–6
   PubMed Web of Science ®Google Scholar
• Lee TM, Su SF, Tsai CH, et al. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science 2001;101:305–11
   PubMed Web of Science ®Google Scholar
• Lederman RJ, Mendelsohn FO, Anderson RD, et al. [TRAFFIC Investigators]. Therapeutic angiogenesis with recombinant fibro-blast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359: 2053–8
   Google Scholar
• Donnelly R, Yeung JM. Therapeutic angiogenesis: a step forward in intermittent claudication. Lancet 2002;359:2048–50
   PubMed Web of Science ®Google Scholar
• Douglas JS, Holmes D, Kereiakes D, et al. CREST Cilostazol for RESTenosis Trial. Presented at the American Heart Association’s Scientific Sessions. November 9–12, 2003, Orlando, FL, USA
   Google Scholar
• Hittel N, Donelly R. Treating peripheral arterial disease in patients with diabetes. Diabetes Obes Metab 2002;4 (Suppl 2):S26–31
   Google Scholar
• National Heart, Lung, and Blood Institute. ATP III at-a-glance: quick desk reference. NIH Publication No. 01–3305. May 2001
   Google Scholar